US equities |
TSLA $362.44 ▲+0.00% MU $931.24 ▲+0.00% SPCX $148.62 ▲+0.00% SNDK $1,394.83 ▲+0.00% SKHY $146.11 ▲+0.00% NVDA $217.23 ▲+0.00% AMD $562.23 ▲+0.00% INTC $95.22 ▼-0.16%
FinancialContent

Oncolytics Biotech Inc. - Common Stock (NQ:ONCY)

0.5476 -0.0024 (-0.44%)
Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oncolytics Biotech Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Why Overall Survival May Be Becoming Oncology’s Most Important Metric (NASDAQ: ONCY)
Via AB Newswire
News headline image
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story
Via ACCESS Newswire
News headline image
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
From World Street Intelligence
Via GlobeNewswire
News headline image
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Registration Momentum Builds Across the Oncology Pipeline
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack
Issued on behalf of Ventripoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
News headline image
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points
Issued on behalf of QSE - Quantum Secure Encryption Corp. 
From USA News Group
Via GlobeNewswire
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
From Equity Insider
Via GlobeNewswire
News headline image
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
THE CHOKE POINT: 5 Assets That Control the Bottleneck
From Equity Insider
Via GlobeNewswire
News headline image
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
Issued on behalf of Ventripoint Diagnostics Ltd. 
From USA News Group
Via GlobeNewswire
News headline image
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Oncolytics Biotech® Provides Update on Special Meeting of Shareholders
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
From FN Media Group LLC
Via GlobeNewswire
News headline image
Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer
From Oncolytics Biotech Inc.
Via Business Wire
News headline image
Oncolytics Biotech® Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy
From Oncolytics Biotech® Inc.
Via Business Wire
News headline image
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
Comparison with multiple landmark first-line metastatic pancreatic ductal adenocarcinoma studies substantiates strong two-year survival benefit of 21.9% vs. 9.2% historical benchmark Consistent... 
Via FinancialNewsMedia
News headline image
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MBIO),(NASDAQ:VSTM),(NASDAQ:CRDF),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >